Randomized phase III trial of a new oral platinum, satraplain (JM–216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer. - Sternberg,CN.; Hetherington,J.; Paluchowska,B. (Proc Am Soc Clin Oncol, 2003)